Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merrimack Pharma

- PMLiVE

ASCO: Merck and BMS trumpet melanoma trials

Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab

Sanofi reception

Sanofi gives up on iniparib and otamixaban

Drops cancer drug and anticoagulant after negative late-stage trials

- PMLiVE

Merck KGaA to research cancer drug with Chinese biotech

German pharma firm teams up with BeiGene on BRAF inhibitor

- PMLiVE

FDA clears two GSK melanoma drugs

Tafinlar and Mekinist approved in the US along with companion diagnostic

- PMLiVE

AstraZeneca offers $443m to buy Omthera

Adds to list of deals to boost flagging pipeline

- PMLiVE

VCCP Health wins Mundipharma’s new product launch business

Agency hired to drive new product launches across Europe

- PMLiVE

A look back at Sanofi’s merger with Synthélabo

This month, in 1999: How two pharma companies came together to create a giant

- PMLiVE

GSK awarded $200m by US government for antibiotic research

Follows state-supported schemes in Europe to combat resistance to antibiotics

- PMLiVE

Roche repeats cancer drugs warning as Avastin faces another NICE rejection

Concerns about future of Cancer Drugs Fund

- PMLiVE

Royalty Pharma raises Elan bid as deals keep coming

Values Elan at about $6.5bn

- PMLiVE

Actavis to buy Warner Chilcott in $8.5bn deal

Combined company will have annual revenues of about $11bn

Sanofi reception

Sanofi reconsiders closure plans in Toulouse after government pressure

Report says research site can remain open with minimal job losses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links